Experience of use of 2-ethyl-6-methyl-3-hydroxypyridine succinate in complex therapy of stable angina
Journal Title: Серце і судини - Year 2019, Vol 0, Issue 3
Abstract
The aim — to evaluate the efficacy and tolerability of the use of different doses (200 and 500 mg/day) of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate (Venokor, Lekhim, Ukraine) in the complex therapy of patients with coronary heart disease and stable angina pectoris of II — III functional class. Materials and methods. The study involved 60 patients with ischemic heart disease and stable angina pectoris of II — III functional class aged 48 to 76 years. The patients were divided into three groups. Patients of the 1st (n = 20) and 2nd (n = 20) groups, in addition to the medical treatment of ischemic heart disease according to the recommendations, were prescribed 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate parenterally at a dose of 200 and 500 mg/day, respectively. Patients of the control group received only standard treatment (b‑blockers, calcium antagonists, acetylsalicylic acid, statins). The effect of treatment was evaluated on the 14th day from the beginning of therapy. Results and discussion. The number of angina attacks per week decreased with the use of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate at a dose of 200 and 500 mg/day compared to patients who were prescribed standard angina therapy (p < 0.05 and p < 0.01, respectively). The need for nitroglycerin tablets decreased statistically significantly in the two main groups compared to the control group (p < 0.01 and p < 0.001, respectively). This decrease was statistically significantly (p < 0.001) greater in patients of the 2nd group compared to the patients of the 1st group. Patients of the two main groups improved their quality of life scores on the scales of pain intensity (p < 0.01), physical functioning, overall mental health (p < 0.01), total physical health score of the SF‑36 questionnaire (p = 0.005). Conclusions. Addition of 2‑ethyl‑6‑methyl‑3‑hydroxypyridine succinate to a standard treatment regimen for patients with coronary heart disease and stable angina pectoris of II — III functional class helps to reduce the need for nitroglycerin and improves patients’ quality of life.
Authors and Affiliations
N. D. Oryshchyn, S. S. Pavlyk, O. Y. Soroka, M. V. Cherkavska, R. Y. Romanyk
Keywords
Related Articles
- EP ID EP673882
- DOI 10.30978/HV2019-3-52
- Views 104
- Downloads 0
Prediction of functional consequences of cerebral ischemic stroke one year after its occurrence
The aim — investigation of independent prognostic factors of minimal dependence in everyday activities one year after ischemic stroke by developing a prognostic mathematical model. Materials and methods. The neurologic...
Use of standard report of transthoracic echocardiography in clinical practice
Recently, transthoracic echocardiography has become a powerful and flexible diagnostic tool providing high quality management of patients with cardiovascular diseases. Development of new technologies and growing number o...
Changes of indices of diurnal blood pressure monitoring under the influence of treatment in patients with essential hypertension complicated with hemorrhagic stroke after early recovery period
The aim — to compare the indices of diurnal blood pressure monitoring (DBPM) in patients with essential hypertension (EH) іn ≥ 6 months after hemorrhagic stroke (HS) before and after treatment with combination of amlodi...
Influence of oxygenator treatment with adaptive composition on changes of blood cells during by-pass surgery
The aim — to assess the method of adaptation of the oxygenator’s contact surface based on recipient's blood serum albumin to the patient’s blood cells changes. Materials and methods. On the basis of the Surgical Center...
The influence of the treatment recommendations completeness on the first day of myocardial infarction with the Q wave of the left ventricle with expansion to the right ventricle on the clinical course of the disease
The aim — to determine the correlation between the implementation completeness of the recommendations for treatment on the first day of the Q-IM of the left ventricle (LV) posterior wall (PW) with expansion to the right...